Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines

Clinical and Vaccine Immunology

Volumn 19, Issue 2, 2012, Pages 128-139

  Giles, Brendan M ^a   Bissel, Stephanie J ^b   DeAlmeida, Dilhari R ^a   Wiley, Clayton A ^b   Ross, Ted M ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEMAGGLUTININ; IMMUNOGLOBULIN G; INFLUENZA VACCINE; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BRONCHUS MUCOSA; CELLULAR IMMUNITY; CLADISTICS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRET; HISTOPATHOLOGY; IMMUNE RESPONSE; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; LETHAL DOSE; MORBIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS ISOLATION; VIRUS PARTICLE; VIRUS REPLICATION; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; FEMALE; FERRETS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84856411125     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05533-11     Document Type: Article

References (57)

1. Askonas B, McMichael A, Webster R. 1982. The immune response to influenza viruses and the problem of protection against infection, p 159-188. In Beare AS (ed), Basic and applied influenza research. CRC Press, Boca Raton, FL.
2. Barouch DH, et al. 2010. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat. Med. 16:319-323.
3. Bissel SJ, et al. 2011. Acute murine H5N1 influenza A encephalitis. Brain Pathol., in press.
4. Bright RA, et al. 2005. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366:1175-1181. (Pubitemid 41393595)
5. Bright RA, Ross TM, Subbarao K, Robinson HL, Katz JM. 2003. Impact of glycosylation on the immunogenicity of a DNA-based influenza H5HA vaccine. Virology 308:270-278. (Pubitemid 36434234)
6. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295:891-894.
7. Brown DM, Dilzer AM, Meents DL, Swain SL. 2006. CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J. Immunol. 177:2888-2898. (Pubitemid 44277804)
8. Centers for Disease Control and Prevention. 2009. Biosafety in microbiological and biomedical laboratories, 5th ed. Centers for Disease Control and Prevention, Atlanta, GA.
9. Chan, M. 11 June 2009, posting date. World now at the start of 2009 influenza pandemic. World Health Organization, Geneva, Switzerland. http://www.who.int/mediacentre/news/statements/2009/h1n1-pandemic-phase6- 20090611/en/index.html.
10. Chen L-M, Davis CT, Zhou H, Cox NJ, Donis RO. 2008. Genetic compatibility and virulence of reassortants derived from contemporary avian H5N1 and human H3N2 influenza A viruses. PLoS Pathog. 4:e1000072.
11. Chen M-W, et al. 2008. A consensus hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc. Natl. Acad. Sci. U. S. A. 105:13538-13543.
12. Chen W, Bennink JR, Morton PA, Yewdell JW. 2002. Mice deficient in perforin, CD4+ T cells, or CD28-mediated signaling maintain the typical immunodominance hierarchies of CD8+ T-cell responses to influenza virus. J. Virol. 76:10332-10337.
13. Crevar CJ, Ross TM. 2008. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol. J. 5:131.
14. Ducatez MF, et al. 2011. Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development. Proc. Natl. Acad. Sci. U. S. A. 108:349-354.
15. Fiore AE, et al. 2010. Prevention and control of influenza with vaccines. MMWR Morb. Mortal. Wkly. Rep. 59:1-62.
16. Garland SM, et al. 2007. Quadrivalent vaccine against human papilloma-virus to prevent anogenital diseases. N. Engl. J. Med. 356:1928-1943. (Pubitemid 46740303)
17. Giles BM, Ross TM. 2011. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine 29:3043-3054.
18. Giuliano AR, et al. 2011. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N. Engl. J. Med. 364:401-411.
19. Govorkova E, Webby R, Humberd J, Seiler J, Webster R. 2006. Immunization with reverse genetics produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J. Infect. Dis. 194:159-167. (Pubitemid 44087186)
20. Hirao LA, et al. 2011. Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J. Infect. Dis. 203:95-102.
21. Horimoto T, Kawaoka Y. 2005. Influenza: lessons from past pandemics, warnings from current incidents. Nat. Rev. Microbiol. 3:591-600. (Pubitemid 41052146)
22. Joo HM, He Y, Sundararajan A, Huan L, Sangster MY. 2010. Quantitative analysis of influenza virus-specific B cell memory generated by different routes of inactivated virus vaccination. Vaccine 28:2186-2194.
23. Kendal AP, Pereira MS, Skehel JJ. 1982. Concepts and procedures for laboratory-based influenza surveillance. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Atlanta, GA.
24. Laddy DJ, et al. 2007. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 25:2984-2989. (Pubitemid 46482729)
25. Laddy DJ, et al. 2009. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J. Virol. 83:4624-4630.
26. Laddy DJ, et al. 2008. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One 3:e2517.
27. Leroux-Roels I, et al. 2007. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580-589. (Pubitemid 47247854)
28. Li C, et al. 2010. Reassortment between avian H5N1 and human H3N2 influenza viruses creates hybrid viruses with substantial virulence. Proc. Natl. Acad. Sci. U. S. A. 107:4687-4692.
29. Lipatov A, Hoffmann E, Salomon R, Yen H-L, Webster R. 2006. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J. Infect. Dis. 194:1040-1043. (Pubitemid 44547643)
30. Lu X, et al. 2006. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 24:6588-6593. (Pubitemid 46107146)
31. Maines TR, et al. 2006. Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc. Natl. Acad. Sci. U. S. A. 103:12121-12126. (Pubitemid 44215821)
32. McBurney SP, Ross TM. 2009. Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines. Vaccine 27:4337-4349.
33. Mitchell JA, Green TD, Bright RA, Ross TM. 2003. Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine 21:902-914. (Pubitemid 36126425)
34. Mozdzanowska K, Maiese K, Gerhard W. 2000. Th cell-deficient mice control influenza virus infection more effectively than Th- and B cell-deficient mice: evidence for a Th-independent contribution by B cells to virus clearance. J. Immunol. 164:2635-2643. (Pubitemid 30115495)
35. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
36. Ninomiya A, Imai M, Tashiro M, Odagiri T. 2007. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 25:3554-3560. (Pubitemid 46575102)
37. Octaviani CP, Ozawa M, Yamada S, Goto H, Kawaoka Y. 2010. High level of genetic compatibility between swine-origin H1N1 and highly pathogenic avian H5N1 influenza viruses. J. Virol. 84:10918-10922.
38. Olsen SJ, et al. 2005. Family clustering of avian influenza A (H5N1). Emerg. Infect. Dis. 11:1799-1801. (Pubitemid 41628374)
39. Prabakaran M, et al. 2010. Neutralizing epitopes of influenza virus hemagglutinin: target for the development of a universal vaccine against H5N1 lineages. J. Virol. 84:11822-11830.
40. Ross TM, Xu Y, Bright RA, Robinson HL. 2000. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat. Immunol. 1:127-131.
41. Santra S, et al. 2010. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat. Med. 16:324-328.
42. Sasaki S, et al. 2008. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One 3:e2975.
43. Sasaki S, et al. 2007. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J. Virol. 81:215-228. (Pubitemid 44975162)
44. Suguitan AL, et al. 2006. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 3:e360.
45. Taubenberger JK, Morens DM. 2009. Pandemic influenza - including a risk assessment of H5N1. Rev. Sci. Tech. 28:187-202.
46. Teijaro JR, Verhoeven D, Page CA, Turner D, Farber DL. 2010. Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. J. Virol. 84:9217-9226.
47. Teshale EH, et al. 2008. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998-2003. Vaccine 26:5830 -5834.
48. Toapanta F, Ross T. 2009. Impaired immune responses in the lungs of aged mice following influenza infection. Respir. Res. 10:112.
49. Tobita K. 1975. Permanent canine kidney (MDCK) cells for isolation and plaque assay of influenza B viruses. Med. Microbiol. Immunol. 162:23-27.
50. Tobita K, Sugiura A, Enomote C, Furuyama M. 1975. Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med. Microbiol. Immunol. 162:9 -14.
51. Treanor JJ, et al. 2001. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19:1732-1737. (Pubitemid 32175735)
52. Ungchusak K, et al. 2005. Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med. 352:333-340.
53. Webby RJ, Webster RG. 2003. Are we ready for pandemic influenza? Science 302:1519 -1522.
54. Webster R, Govorkova E. 2006. H5N1 influenza: continuing evolution and spread. N. Engl. J. Med. 355:2174 -2177.
55. World Health Organization. September 2011, posting date. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses for the development of candidate vaccine viruses for pandemic preparedness. http://www.who.int/influenza/resources/documents/2011-09-h5-h9- vaccinevirusupdate.pdf.
56. World Health Organization. 15 December 2011, posting date. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. http://www.who.int/influenza/human-animal-interface/EN-GIP- 20111215CumulativeNumberH5N1cases.pdf.
57. Yan J, et al. 2007. Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol. Ther. 15:411-421. (Pubitemid 46111893)